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their recommendations for the implementation, the target-group, the rescreening
interval and the primary screening methods of the programs proposed, and to
recommend the social insurance reimbursement level. RESULTS:Of the 33 experts
invited, 26 (78%) accepted to participate. The vast majority of them supported the
implementation of an NSP for breast cancer, cervical cancer, colorectal cancer,
vascular risk and abdominal aortic aneurysm. Both the rescreening interval and
the primary screening method of each of the programs were considered adequately
effective. The biggest debate was focused on the target-group of the colorectal
cancer and the abdominal aortic aneurysm program. All of the experts argued that
social insurance should fully reimburse the programs for the individuals that fulfill
the eligibility criteria. Otherwise the cost should be borne by the individual, accord-
ing to the 77% of the panelists. 68% of the experts argued that when the eligibility
criteria are not fullfiled but the individual is referred by a general practitioner or a
specialist for screening, social insurance should partly reimburse the cost.
CONCLUSIONS: Despite any debates especially on the target-group of the pro-
grams, all of the programs were deemed necessary, stressing the need for orga-
nized screening in order to reduce mortality and morbidity from certain conditions
and to optimize the allocation of resources invested in secondary prevention
PCN155
THE CHALLENGES OF ESTIMATING COSTS OF PALLIATIVE CARE: A
SYSTEMATIC LITERATURE REVIEW
Hendry L1, Tumur I2, Farquharson R3, Kroes MA3
1Pfizer Ltd, Tadworth, Surrey, UK, 2Pfizer Ltd, Tadworth, Surrey , UK, 3Abacus International,
Bicester, Oxfordshire, UK
OBJECTIVES: To systematically review the literature for methods of estimating the
costs of palliative care and to assess which costs are included in palliative care.
METHODS: Preliminary scoping of health technology assessment appraisals iden-
tified high degree of heterogeneity in how palliative care is defined, in terms of the
type of care, and the models and settings of delivery. To focus the review, patients
with metastatic renal cell carcinoma (mRCC) were chosen as the reference popu-
lation, in keeping with the PICO (population, indication, comparison, outcome)
approach to formulating research questions. Relevant search terms were identified
and searches conducted in EMBASE, MEDLINE, Cochrane library and Econlit. Re-
sults were filtered using pre-specified selection criteria and data extracted into a
pre-defined template. RESULTS: Without a specified patient population, database
searches identified almost 17,000 records; mRCC focussed searches identified 1,172
records. From mRCC searches 66 full text publications were assessed and only 17
met pre-defined inclusion criteria. Of these publications, nine assessed surgery
costs; five were cost-effectiveness assessments; and three assessed burden of dis-
ease. Cost data collected was largely based on expert opinion and country-specific
assumptions (with potential bias) making generalisation difficult. Notable levels of
heterogeneity between the included publications (publication type, year, country
and perspective) precluded consistent, qualitative synthesis of the data.
CONCLUSIONS: Despite focussing on a specific disease population, high levels of
heterogeneity in the reporting and study of palliative care, in terms of setting and
delivery, prevented a robust interpretation of the data. A key driver of this hetero-
geneity may be the fact that palliative care is delivered in a variety of settings, using
diverse models of care. Evidence-based assessments of costs of palliative care
present methodological challenges. Therefore, we see a need for agreement on the
definitions and parameters of palliative care, which would greatly assist future
decision making.
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OBJECTIVES: Australia has the highest incidence of melanoma in the world, how-
ever little published information exists regarding treatment patterns. A study was
undertaken to define current treatment options offered to Australian patients.
METHODS:A survey was developed from interviews with 7 scientific experts treat-
ing melanoma in Australia. Algorithms outlining referral and treatment patterns
across all stages of melanoma were derived and validated by dermatologists and
general surgeons for early stage and medical oncologists for later stage disease.
RESULTS: A total of 115 oncologists were identified as treating melanoma in Aus-
tralia and 26% of those responded. In addition, a sample of 40 dermatologists and
surgeons were contacted and 43% of those participated. Results demonstrated that
nearly all patients with local or locoregional melanomas undergo radical excision
of their primary lesion; whereas 73.1% of patients with metastatic melanoma have
their primary lesion excised. For metastatic disease, the majority of oncologists
reported that current 1st line chemotherapy is dacarbazine (DTIC) (85%) or fote-
mustine (77%), although a large percentage also reported enrolling patients in clin-
ical trials (73%). Nine oncologists (36%) surveyed indicated that they expect overall
survival (OS) of 7-9 months after initiation of 1st line chemotherapy. Oncologists
also reported that 48% of patients who relapse after 1st line therapy receive 2nd
line therapy, of which enrollment into a clinical trial (69%) or treatment with fote-
mustine (62%) are the most common treatment options. Approximately half (48%)
of oncologists surveyed expect OS in 2nd line to be 3-6 months. The most common
sites for development of metastases were reported to be lung (48.0%), liver (47.6%)
and brain (38.0%). CONCLUSIONS: To our knowledge, this is the first survey con-
ducted to understand melanoma treatment patterns in Australia. This study pro-
vides information for evidence-based decision makers to understand how health
resources are utilised in the treatment of melanoma in Australia.
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OBJECTIVES: Access to innovative medicines is sometimes challenging due to is-
sues related to affordability, attributable at least in part to the heterogeneity and
design of health insurance coverage. A support program (Program) to help patients
requesting assistance in accessing oral oncology agents was evaluated to deter-
mine if it facilitated their access to medication.METHODS: Anonymized data from
a random sample of patients enrolling in the Program in 2008-2009 and a random
sample of control patients from Risk Evaluation and Mitigation Strategies (REMS)
programs for lenalidomide and thalidomide were analyzed. Specifically, patient
characteristics, type of assistance provided, and dispensing outcomes (proportion
successfully dispensed medication, time from prescription authorization to first
dispense, reason for non-dispense, and proportion of Program patients seeking
further assistance following their initial request) were assessed. RESULTS: A ran-
dom sample of 1000 Program and 1000 control patients was evaluated. Most pa-
tients had a primary diagnosis of multiple myeloma or of myelosdysplastic syn-
dromes. Despite the expressed need for assistance in accessing medication among
the Program patients, the percentage of Program patients receiving medication
compared with patients in the control group was not statistically different (89% vs.
91%, respectively; p 0.270), with a difference in median time to dispense of 3 days.
Ninety-two percent of Program patients successfully obtained durable access to
oral medication. CONCLUSIONS: The results suggest that a support program for
patients needing assistance in a complex health insurance environment can effec-
tively achieve a goal of helping them to obtain access to therapies prescribed by
their physicians. Research should be conducted to better understand which ele-
ments of such programs are most valuable to patients, and therefore would be
considered best practices for such programs.
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OBJECTIVES: As the potential role of genetic testing in disease prevention and
management grows, so does concern about differences in uptake of genetic testing
across social and racial groups. Characteristics of how genetic tests are delivered
may influence willingness to undergo testing and potentially alter disparities in
testing. METHODS: Conjoint analysis study of the effect of three characteristics of
genetic test delivery on willingness to undergo genetic testing for cancer risk. Data
were collected using a random digit dialing survey of 337 individuals living in the
US. Measures included conjoint scenarios, health care system distrust (values and
competence subscales), health insurance coverage, and sociodemographic charac-
teristics. Three attributes were studied: disclosure of test results to the health
insurer, provision of the test by a specialist or primary care doctor, race specific or
race neutral marketing. RESULTS: In adjusted analyses, disclosure of test results to
insurers, having to get the test from a specialist, and race specific marketing were
all inversely associated with willingness to undergo the genetic test, with the great-
est effect for the disclosure attribute. Racial differences in willingness were not
statistically significant (p0.07) and the effect of the attributes on willingness to
undergo testing did not vary by patient race. However, the decrease in willingness
with insurance disclosure was greater among individuals with high values distrust
(p0.03) and the decrease in willingness to undergo testing from specialist access
was smaller among individuals with high competence distrust (p0.03).
CONCLUSIONS: Several potentially modifiable characteristics of how genetic tests
are delivered are associated with willingness to undergo testing. The effect of two
of these vary according to the level of health care system distrust, suggesting that
policy decisions about delivery of genetic testing may influence differences in up-
take across patient subgroups defined by levels of distrust rather than by race.
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OBJECTIVES: Lung cancer is the most common cause of cancer mortality in Europe.
Gefitinib and erlotinib are two epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) registered for patients with non–small-cell lung cancer
(NSCLC). Patients with a positive EGFR-mutation benefit from first line treatment
with EGFR-TKIs. However, since worse outcomes are observed among patients
without the mutation, testing is crucial. Our study aims to investigate the use of
diagnostics and treatment with EGFR-TKI of patients with NSCLC in daily practice.
METHODS: We sent a semi-structured questionnaire to physicians and laborato-
ries about EGFR-mutation tests and treatment strategies. Furthermore, sales num-
bers of gefitinib and erlotinib were obtained to calculate the number of patients
treated with EGFR-TKI. RESULTS: Response covered more than two third of the
Dutch lung cancer population. Approximately 70% of the patients, which should
have been tested for EGFR-mutation, were tested. Sub-analyses revealed large re-
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gional differences ranging from testing 44% to more than 100% of the eligible pa-
tients, implying overuse of diagnostic tests in the latter case. Moreover, there was
a long waiting-time before results of EGFR-mutation tests were available (mean
11.9 days, SD 4.3 days). Considering treatment, on average about 45% of the eligible
patients were treated with EGFR-TKI in the first line. Regional variation was ob-
served ranging from 32% to 84%. Furthermore, extensive treatment variation was
observed, which was not according to current clinical guidelines. CONCLUSIONS:
The probability of testing patients for EGFR and treatments given varied consider-
ably. This did not correspond with current clinical guidelines. Less than 50% of the
eligible patients received EGFR-TKI in the first line. Reasons may be the long wait-
ing-time for test results, physicians experience and individual patient character-
istics. However, the large regional differences plead for optimal use of existing
diagnostic and treatment strategies to improve outcomes for this patient group.
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OBJECTIVES: To determine the extent of social inequality in uptake of prostate
cancer screening in Ireland and compare inequalities across groups for whom the
cost effectiveness of screening is thought to vary. METHODS: A series of decompo-
sition analyses of inequalities in uptake of prostate cancer screening were under-
taken using data collected as part of a large population based survey in the Republic
of Ireland (SLAN 2007). Separate analyses were conducted for individuals differen-
tiated by age on the basis of reported differences in the cost effectiveness of screen-
ing. A range of explanatory variables were used to explore the role of non-need
factors in inequalities including education and possession of private medical
insurance.RESULTS:Overall uptake of prostate screening in men aged 40 years and
over in the preceding 12 months was 23.81%. Uptake was highest among those in
the age group where the cost effectiveness of screening was deemed to be highest
(based on the findings of the European Randomised Study of Prostate Cancer (ER-
SPC) trial). The lowest socioeconomic inequality was also observed among this age
group. The decomposition of the concentration indices showed that possession of
private insurance was the largest determinant of inequality among those 55-69
(36%) and remained a significant determinant among those aged 40-54 (26%) and
aged 70 and over (17%). CONCLUSIONS: The decision to engage with screening is
one likely to be taken in conjunction with a healthcare professional and reflect an
assessment of the expected costs and benefits of screening to the individual.
Where evidence as to the merits of screening is ambiguous and financial incentives
to screen are evident patterns of uptake may emerge that does not represent an
appropriate use of resources and warrant greater scrutiny. KEY WORDS: Prostate
Cancer PSA Test Screening Incidence Diagnosis Concentration Indices Decompo-
sition Analysis
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OBJECTIVES: The European Parliament called for a greater focus on viral hepatitis
and hepatocellular carcinoma (HCC), yet there has been little action on this decla-
ration. We conducted a needs assessment for HCC control and tested needs con-
cordance in five European countries. METHODS: Clinical, policy and patient advo-
cacy stakeholders were purposively sampled from France, Germany, Italy, Spain,
and Turkey. Ten indicators were assessed subjectively: clinical education; early
risk assessment; HBV strategy; HCV strategy; life-style risk factors; national statis-
tics; funding for detection; funding for treatment; political awareness; and public
awareness. Results were compared to a benchmark using a Z-score and concor-
dance tested via the F-test. RESULTS: One hundred participants (response
rate37%) were drawn equally from the 5 countries. Respondents self-identified as
having influence at the local (33%), national (39%), or international (28%) level.
Greatest need is for improvement in life-style risk factors (Z-9.51), political
awareness (Z-7.97), and public awareness (Z-7.67), while the least need is for
improved HBV strategies (Z10.40). Overall, France performed best (Z4.26), and
Turkey worst (Z-2.54). Significant discordances in needs (P0.05) were found for
half of the factors (funding for treatment and detection, public awareness, HBV
strategy and national statistics), but concordance was accepted for the remaining
factors. CONCLUSIONS: We demonstrated a statistical method for conducting a
needs assessment for HCC control in Europe and found that the greatest needs are
for improving life-style risk factors (especially related to obesity and diabetes) and
political and public awareness. Despite being a cost-effective measure, HBV control
strategies are needed the least (mainly due to prior adoption). With both concor-
dant and discordant needs, there are roles for both national and European-wide
efforts in HCC control. For example, the European parliament should lead efforts in
driving political awareness and lifestyle risk factors, while member countries
should focus on public awareness.
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OBJECTIVES:Overall 2506 patients gained access (from a total of 2880 applications)
for oncology treatment from the Cancer Drugs Fund within the first 6 months of its
launch. However, there are significant variations in the number of applications that
different Strategic Health Authorities (SHAs) are able to process and approve. This
study aims to assess the underlying reasons for the observed inter regional vari-
ability in the application rates, processing and outcomes within the Cancer Drugs
Fund from October 2010 to March 2011. METHODS: The results on the application
rates from an audit undertaken by Rarer Cancers Foundation using the Freedom of
Information Act were analysed, especially, the change in application rate over time
and the outcomes of these requests. The analysis led to the development of a
framework to understand the key factors influencing the application rates and its
outcomes, which was then validated through a telephone survey of key SHAs in
2011. RESULTS: Along with significant variations in the application rate, there
appears to be a north-south divide, with SHAs in the south of England approving a
lower proportion of applications. Some of the underlying reasons were identified to
be linked with administration costs, levels of routine access to cancer treatments
(which itself vary according to the area of the country) and ‘timely’ decision-mak-
ing ability. CONCLUSIONS: Some of the notable practices identified towards expe-
diting the processing of applications can form recommendations for robust process
development in future for the upcoming clinical commissioning consortia to guide
their commissioning activities. Future steps can include benchmarking of their
application approval rates by clinical commissioning consortia (and SHAs until
2013) against that in other region and take action to identify the outliers and ad-
dress the causes of this.
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OBJECTIVES: Substantial differences in cancer-related mortality rates among the
16 provinces of Poland exist. Over the last 10 years the differences between the
highest and the lowest observed standardized mortality rates varied at 33.9% to
54.2% in female population and at 24.1% to 40.9% in male population. The differ-
ences in mortality rates cannot be explained only by differences in cancer inci-
dence rates among the provinces since weak correlation between both this values
exist (Pearson’s correlation r0.33 and r0.36 in male and female population, re-
spectively). There are also substantial differences in availability of oncology care
among the provinces since to some extent each of 16 regional departments of the
National Health Fund (NHF) pursues its own health policy. The aim of this study
was to estimate whether the differences in availability of oncology care are respon-
sible for differences in cancer-related mortality among the provinces of Poland.
METHODS: We used NHF data on contracts for oncology hospital and ambulatory
care in 2008 and the National Cancer Registry (NCR) data on age-standardized
mortality rates due to cancer in 2008. Data on hospital and ambulatory care and
incidence data for each province were used to estimate availability of oncology care
per cancer patient. Incidence data were used due to lack of cancer precise preva-
lence data. RESULTS: We have found no strict correlation between mortality rates
and availability of hospital care with Pearson’s correlation r-0.01 and r-0.05 in
male and female population, respectively. Surprisingly weak positive correlations
between mortality rates and availability of ambulatory care were found with Pear-
son’s correlation r0.36 and r0.45 in male and female population, respectively.
CONCLUSIONS: Further research, extended beyond simple relation between clin-
ical outcomes and health care service financing is needed to explore inter-prov-
inces variability. International Research Project on Financing Quality in Healthcare
InterQuality, is aimed to address those discrepancies in health care.
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OBJECTIVES: Human Papilloma Virus (HPV) vaccination programs among women
have been successfully implemented in Europe. Burden of HPV-related cancers is
rising in Europe in men and represents around 30% of the overall HPV-related
burden in both genders. Vaccinating girls have an indirect protective impact on
males but doesn’t avoid the whole HPV burden. Study objective was to have a first
estimate of the incremental benefits of vaccinating males and females compared to
females only, in Europe. METHODS: An Excel-based model was developed to esti-
mate impact of vaccinating boys and girls with a quadrivalent-HPV6/11/16/18 vac-
cine on HPV-related diseases: anal, penile, head and neck, vaginal, vulvar and
cervical cancers and genital warts. Epidemiological reductions due to vaccination
were derived from a US dynamic transmission model. Epidemiological data and
demographic inputs came from published literature. The analysis estimates the
incremental clinical benefits of adding a cohort of 12-years old boys to a 12-years
old girls vaccination program. Seventy percent vaccine coverage rates were as-
sumed for both strategies. RESULTS: A validation of this model was achieved by
being able to replicate US dynamic model results (number of cases avoided). In
Europe, female-only vaccination would result in a 61% reduction in males HPV-
related cancers (at steady state; 100 years). Adding a cohort of boys would increase
this result to 86% and would avoid significant additional HPV-related diseases
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